000			01999 a2200577 4500
005			20250517223100.0
264		0	_c20190624
008			201906s 0 0 eng d
022			_a1029-2403
024	7		_a10.1080/10428194.2018.1459605 _2doi
040			_aNLM _beng _cNLM
100	1		_aWang, Zhao
245	0	0	_aRecombinant human thrombopoietin (rh-TPO) for the prevention of severe thrombocytopenia induced by high-dose cytarabine: a prospective, randomized, self-controlled study. _h[electronic resource]
260			_bLeukemia & lymphoma _c12 2018
300			_a2821-2828 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntimetabolites, Antineoplastic _xadministration & dosage
650	0	4	_aCytarabine _xadministration & dosage
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Administration Schedule
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLymphoma, Non-Hodgkin _xblood
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPlatelet Count
650	0	4	_aPlatelet Transfusion _xstatistics & numerical data
650	0	4	_aProspective Studies
650	0	4	_aRecombinant Proteins _xadministration & dosage
650	0	4	_aThrombocytopenia _xblood
650	0	4	_aThrombopoietin _xadministration & dosage
650	0	4	_aTreatment Outcome
650	0	4	_aYoung Adult
700	1		_aFang, Xiaojie
700	1		_aHuang, He
700	1		_aHong, Huangming
700	1		_aLi, Xueying
700	1		_aGuo, Chengcheng
700	1		_aFu, Xiaohong
700	1		_aZhang, Mengping
700	1		_aLam, Sio Teng
700	1		_aLi, Shanshan
700	1		_aLi, Fangfang
700	1		_aPeng, Chen
700	1		_aTian, Ying
700	1		_aLin, Tongyu
773	0		_tLeukemia & lymphoma _gvol. 59 _gno. 12 _gp. 2821-2828
856	4	0	_uhttps://doi.org/10.1080/10428194.2018.1459605 _zAvailable from publisher's website
999			_c28537328 _d28537328